Streetbeat News

Regulatory

BCTX

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW) (TSX:BCT) has reported unprecedented anti-tumor activity in tumor models by its next generation breast and prostate cancer immunotherapies. The FDA has authorized Bria-OTS™ Investigational New Drug Application (IND), opening the path to the clinic. The company's data shows broad immune system responses to the next generation immunotherapies compared with those of the earlier formulation. The company expects the administration of personalized BRIA-OTS+™ and BRIA-PROS+™ immunotherapies to provide safe and effective treatment options for cancer patients.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:35 pm

BAM

CCJ

Cameco and Brookfield Asset Management have received all necessary regulatory approvals for their joint acquisition of Westinghouse Electric Company. The transaction is expected to close on November 7. Cameco will finance its share of the acquisition using a $600 million term loan and available cash, and will not be utilizing the $280 million bridge commitment.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:33 pm

SPY

The USA participation rate for October was reported at 62.7%, slightly lower than the prior rate of 62.8%.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:30 pm

SPY

The USA Nonfarm Payrolls for October came in at 150K, lower than the estimated 180K and significantly below the prior figure of 297K.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:30 pm

SWAV

Shockwave Medical announced that the US Centers for Medicare & Medicaid Services has established a Category I Current Procedural Terminology Add On Code for Coronary Intravascular Lithotripsy Procedures, effective from January 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:20 pm

ARDX

Ardelyx has shared data from its studies of XPHOZAH at the ASN Kidney Week 2023. The data is expected to provide insights into the effectiveness of the drug in treating kidney diseases.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:12 pm

CVRX

The Centers for Medicare and Medicaid Services has reassigned CVRx's Barostim Implant Procedure for procedures performed in the outpatient setting as part of the 2024 Medicare Hospital Outpatient Prospective Payment System Final Rule. CVRx is focused on the development and commercialization of the Barostim™ System, a FDA-approved medical technology that uses neuromodulation to improve the symptoms of heart failure.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:12 pm

PROF

Profound Medical has announced that the Centers for Medicare & Medicaid Services (CMS) has extended the temporary 'code' for TULSA to the Ambulatory Surgical Center (ASC) setting. This will go into effect from January 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:09 pm

PSTV

Plus Therapeutics has been granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda, a drug for breast cancer treatment with leptomeningeal metastases.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 11:05 am

HUT

Hut 8 Mining Corp has received court approval for its stalking horse bid for four natural gas power plants and a Bitcoin mine in North Bay. This acquisition will allow Hut 8 to control its energy costs and increase its Bitcoin mining capacity.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 10:53 am